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Purpose: To evaluate the efficacy and safety of oral mineralocorticoid-receptor
antagonist (MRa) therapy in three clinical presentations of nonresolving central serous
chorioretinopathy (CSCR) with chronic epitheliopathy.
Methods: Retrospective case series of consecutive patients with nonresolving CSCR
treated with oral eplerenone or spironolactone. Treatment criteria were: persistent
CSCR with subretinal fluid (SRF) lasting longer than 4 months; recurrent CSCR with
SRF lasting longer than 2 months; persistent CSCR (SRF  4 months) with fundus
autofluorescence gravitational tracks. Outcomes at 1, 3, and 6 months were: foveal
SRF height, central macular thickness (CMT), subfoveal choroidal thickness (SFCT),
best-corrected visual acuity (BCVA), and occurrence of side effects.
Results: Among 54 eyes from 42 patients (mean age: 53 years), mean foveal SRF, CMT,
and SFCT decreased significantly at 1, 3, and 6 months after treatment initiation. Mean
BCVA improved significantly at 6 months. In the subgroup analysis, mean foveal SRF,
CMT, and SFCT decreased significantly at 3 and 6 months in the persistent and
recurrent groups. In persistent cases with tracks, a significant diminution of mean CMT
and SFCT was achieved at 6 months. Treatment-related side effects were observed in
6 patients, prompting treatment discontinuation in one case.
Conclusion: Response to treatment was observed in the three subgroups. In
persistent CSCR with tracks the response was delayed compared with persistent and
recurrent cases, suggesting that longer treatment durations would be beneficial in
patients with gravitational tracks of RPE alteration.
Translational Relevance: The clinical response to oral MRa is consistent with the
involvement of the mineralocorticoid pathway in CSCR pathogenesis.
Introduction
Central serous chorioretinopathy (CSCR) is a
vision-threatening condition predominantly affecting
middle-aged males and characterized by serous retinal
detachments in the macular area. Acute CSCR
episodes usually resolve within 4 months without
visual consequences. Yet, a fraction of these cases
may persist or recur.1 The chronic form, also known
as ‘‘diffuse retinal pigment epitheliopathy,’’2 presents
with widespread RPE changes and atrophy associated
to variable degrees of intraretinal cysts.3 These
alterations persist over time, leading to pronounced
visual loss.4,5 In addition, choroidal thickening, or
‘‘pachychoroid,’’ is frequently observed in acute and
chronic CSCR.
There is no consensus regarding the optimal timing
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and the most suitable option for treatment of
nonresolving CSCR. Whereas observation is the
appropriate first-line approach for acute episodes,6
long-standing subretinal detachments may induce
irreversible photoreceptor damage, and treatment is
therefore justified in these cases.7
To date, available physical treatments target
specific features presumably involved in CSCR
pathophysiology. Verteporfin photodynamic therapy
(PDT) aims at reducing choroidal vascular hyper-
permeability and congestion.8 Laser photocoagula-
tion attempts to seal RPE leakage sites.9 Both
treatments are aimed at focal leakage areas, while
there is evidence of diffuse and bilateral changes
affecting the choroid and the RPE, particularly in
chronic CSCR.
Recently, significant progress has been made on
our understanding of a hypothesis regarding molec-
ular events triggering choroidal vasodilatation in
CSCR.10,11 Inappropriate activation of the mineralo-
corticoid receptor (MR) in choroidal endothelial cells,
either by its natural ligand, aldosterone, or by
glucocorticoids that have a high affinity for MR,
induces upregulation of the vasodilator potassium
channel KCa2.3 (calcium-dependent channel) and
smooth muscle cells relaxation in the choroidal
vasculature.
Therefore, spironolactone and eplerenone, two
oral MR antagonists, have been proposed as systemic
treatments for nonresolving CSCR, with reports of
significant anatomical and functional responses in
three series12–14 and one randomized trial.15 However,
little data is available regarding the efficacy of these
treatments on the various clinical forms of CSCR.
Based on our experience of CSCR management using
this novel approach, this retrospective interventional
study aimed to evaluate the effect of oral MR
antagonists in three clinical presentations of non-
resolving CSCR.
Methods
For this retrospective interventional study, re-
cords of consecutive patients with nonresolving
CSCR followed up at Jules-Gonin Eye Hospital or
Moorfields Eye Hospital, who were initiated treat-
ment with oral eplerenone or spironolactone between
April 2013 and August 2014 were reviewed. This
study involving human participants was designed in
accordance with the tenets of the 1964 Declaration of
Helsinki and its later amendments and with the
ethical standards of the Ethics Committee of the
Swiss Federal Department of Health (n8 CER-VD
19/15 and 20/15) and the institutional review board
at the NIHR Moorfields Biomedical Research
Centre (n8 ROAD 15/031). The need of formal
informed consent was waived due to the retrospec-
tive nature of the study.
‘Nonresolving CSCR with chronic epitheliopathy’
was defined by the presence of a sensory retinal
detachment associated with areas of RPE atrophy and
pigment mottling, manifesting on fluorescein angiog-
raphy as extended or multifocal areas of granular
hyperfluorescence, possibly containing one or several
subtle leaks.16 Patients presenting features suggestive
of an overlap with neovascular age-related macular
degeneration, such as drusen, retinal hemorrhages,
hard exudates or type 1 choroidal neovascularisation
on dynamic and static indocyanine green angiography
(ICG) were excluded, as well as patients who had
previously responded to anti-vascular endothelial
growth factor (VEGF) therapy. Patients with fol-
low-up shorter than 3 months or with simultaneous
treatment by PDT, laser photocoagulation, or intra-
vitreal anti-VEGF were also excluded. Three groups
were defined according to their history and retinal
findings reflecting disease duration: (1) persistent
CSR defined as nonresolving subretinal fluid for at
least 4 months of observation, without knowledge of
previous episodes, (2) recurrent CSCR defined as an
active CSCR episode occurring at least 3 months after
a previous episode, with nonresolving subretinal fluid
for at least 2 months, and (3) persistent CSCR with
tracks defined as nonresolving subretinal fluid for at
least 4 months with gravitational tracks on fundus
autofluorescence.
Baseline and monthly evaluations included best-
corrected visual acuity (BCVA), comprehensive oph-
thalmological examination, and multimodal imaging
by spectral-domain OCT and fundus autofluores-
cence (Spectralis, Heidelberg Engineering, Heidel-
berg, Germany). Fluorescein angiography, dynamic
and static ICG angiography were performed at
baseline (Spectralis).
Decision to treat with eplerenone or spironolac-
tone for this off-label indication was made in
agreement with each patient after informed consent.
Treatment by eplerenone (Inspra; 25–50 mg daily;
Pfizer AG, Zu¨rich, Switzerland or Surrey, UK) or
spironolactone (25–75 mg daily; Aldactone; Pfizer
AG, Zu¨rich, Switzerland or Sandwich, Kent, UK;
Xenalon; Mepha Pharma AG, Basel, Switzerland)
was administered orally in the morning. Treatment
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was discontinued after complete resolution of subret-
inal fluid.
Based on recommendations by the Swiss Agency
for Therapeutic Products (Swissmedic)17 and the
electronic Medicines Compendium (eMC, Data-
pharm, Leatherhead, UK)18 treatment by mineralo-
corticoid receptor antagonists was not initiated to
patients presenting the following contraindications:
pregnancy, severe heart, hepatic, or renal failure
(creatinine clearance  30 mL/min), baseline kalemia
greater than 5.0 mEq/L, concurrent treatment by
potassium-sparing diuretics, angiotensin-converting
enzyme inhibitors, angiotensin-2 receptor antagonists,
nonsteroidal anti-inflammatory drugs, lithium, or
potent CYP3A4 inhibitors. For patients older than
60 years of age, and those on treatment for a chronic
condition (such as hypertension, diabetes, cardiovas-
cular disease), MR-antagonists were introduced after
agreement with the attending physician.
Kalemia was monitored at baseline, after 1 month
and subsequently every 3 months in case of normal
levels.19 In case of hyperkalemia greater than or equal
to 5.0 mEq/L, MR antagonist dosing was reduced,
and Kþ levels were controlled closely. In case of
hyperkalemia greater than or equal to 5.5 mEq/L,
treatment was interrupted. The treatment scheme is
represented in Figure 1.
The primary outcome was the height of subretinal
fluid (SRF) at the fovea. Secondary outcomes were:
central macular thickness (CMT), subfoveal choroidal
thickness (SFCT), BCVA, and occurrence of side
effects. In cases with extrafoveal SRF at presentation,
the maximal elevation of SRF was also measured.
CMT was measured from RPE to internal limiting
membrane via the built-in Spectralis OCT software
using the central field of an Early Treatment Diabetic
Retinopathy Study (ETDRS) grid projected onto the
thickness map. SFCT was evaluated manually on
enhanced-depth imaging horizontal OCT scans,
except when image quality was insufficient to
discriminate the interface between outer choroid and
sclera. All parameters were measured at baseline, 1, 3,
and 6 months after treatment introduction. For each
anatomical parameter (foveal SRF, CMT, SFCT),
patients were classified as ‘responders’ when this
parameter decreased from baseline to the last time-
point available, and as ‘nonresponders’ otherwise. To
compute means, Snellen BCVA values were converted
to logarithm of the minimum angle of resolution
(LogMAR). Statistical analyses were performed using
Figure 1. Treatment scheme for mineralocorticoid-receptor antagonists in patients with nonresolving CSCR. Kþ, potassium plasma level
monitoring; M1, month 1; M3, month 3; MR-a, mineralocorticoid-receptor antagonists; PDT, photodynamic therapy.
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Wilcoxon paired test, Mann-Whitney U test, and Chi-
square tests where appropriate on GraphPad Prism
(Version 5.0, GraphPad Software Inc., La Jolla, CA).
P values inferior to 0.05 were considered significant.
Results
Cohort Description
Among 50 CSCR patients (67 eyes) who received
oral MR antagonists during the study period, 42
patients (54 eyes) met the inclusion criteria, consisting
of 37 men and 5 women. Mean age was 53.1 years
(range, 32–81). According to their history at presenta-
tion, 20 eyes were classified as persistent CSCR, 19 eyes
as recurrent CSCR, and 15 eyes as persistent CSCR
with tracks. Eyes with persistent CSCR with tracks had
significantly more advanced RPE alterations on
fluorescein angiography, more frequent intraretinal
cysts, photoreceptor atrophy, and flat irregular pigment
epithelial detachments on OCT. Comparative imaging
findings according to the clinical subtype are summa-
rized in the Supplementary Table S1.
Duration of disease since diagnosis of CSCR was 5.4
years in the whole cohort, and 4.1 years, 4.3 years, and
8.7 years in the persistent, recurrent, and persistent-
with-tracks groups, respectively. Among the persistent
cases with tracks, 9 of 15 eyes (60%) had a duration
that exceeded 10 years. Overall, 12 subjects received
spironolactone, 22 received eplerenone, and 8 received
both treatments sequentially. Clinical and treatment
characteristics are detailed in Table 1.
Treatment Effect
When considering all patients together, mean
foveal SRF decreased from 93 lm at baseline to 65
(P¼ 0.009), 39 (P , 0.0001), and 35 lm (P , 0.0001)
at 1, 3, and 6 months, respectively (Fig. 2). Among 42
eyes with foveal SRF at baseline, 16 (38%) and 21 eyes
(50%) showed a complete resolution of foveal SRF at
3 and 6 months, respectively. Notably, eyes with total
foveal SRF resolution at 6 months had a greater
relative foveal SRF decrease at 3 months than those
without resolution (69% vs. 21%, P , 0.0001).
Mean CMT decreased from 342 lm at baseline to
310 (P ¼ 0.002), 288 (P , 0.0001), and 285 lm (P ¼
0.0003) at 1, 3, and 6 months, respectively (Fig. 3).
Table 1. Baseline Clinical Characteristics and Treatments Received
All Patients
CSCR Subtype
Persistent Recurrent
Persistent
With Tracks
Baseline patients characteristics
Number of subjects n ¼ 42 n ¼ 17 n ¼ 15 n ¼ 10
Age, y 53.1 54.1 47.5 59.7
M/F (N) 37/5 13/4 14/1 10/0
Bilateral CSCR (N) 17 3 6 8
History of corticosteroid exposure 13 9 3 1
Baseline eyes characteristics
Number of eyes n ¼ 54 n ¼ 20 n ¼ 19 n ¼ 15
Duration since CSCR diagnosis, y (range) 5.4 (0.4–14.3) 4.1 (0.4–14.3) 4.3 (0.4–9.8) 8.7 (0.5–12.4)
Subfoveal SRF (N) 42 17 17 8
Extrafoveal SRF (N) 9 3 2 4
Intraretinal cysts (N) 8 3 0 5
Previous laser or PDT treatment (N) 9 3 3 3
Previous intravitreal anti-VEGF (N) 11 4 3 4
Treatment by oral mineralocorticoid receptor antagonist (patients treated, N)
Spiro 12 6 3 3
Eple 22 7 9 6
Spiro, then eple 7 3 3 1
Eple, then spiro 1 1 0 0
Spiro, spironolactone; Eple, eplerenone; SRF, subretinal fluid; PDT, photodynamic therapy; VEGF, vascular endothelial
growth factor.
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Accurate determination of the SFCT was possible in
48 eyes. Mean SFCT decreased from 474 lm at
baseline to 465 (P¼ 0.039), 434 (P¼ 0.0007), and 446
lm (P , 0.0001) at 1, 3, and 6 months, respectively
(Fig. 4).
In a subset of 12 eyes that presented extrafoveal
SRF at baseline, the maximal SRF height decreased
from 101 lm at baseline to 42 (P ¼ 0.022), 89 (P ¼
0.46), and 72 lm (P ¼ 0.039) at 1, 3, and 6 months,
respectively.
Mean LogMAR BCVA improved from 0.28 at
baseline to 0.23 at 6 months (P ¼ 0.041).
In a subgroup analysis according to the three
clinical presentations, mean foveal SRF and CMT
diminished significantly at 1, 3, and 6 months in both
the persistent and recurrent groups (Figs. 2 and 3).
Mean SFCT also decreased significantly at 3 and 6
months in these groups (Fig. 4). In persistent cases
with tracks, a near-significant decrease in foveal SRF
was observed after 6 months of treatment (P¼ 0.058;
Fig. 2). In this group, a significant diminution of the
mean CMT and SFCT was achieved only at 6 months
(Figs. 3 and 4). Results are reported in Table 2 and
treatment responses are illustrated in Figure 5.
Noticeably, mean SFCT at baseline was higher in
the recurrent group (544 lm) than in the two other
groups (431 lm; P ¼ 0.016).
The kinetics of foveal SRF decrease differed
between the three groups, with an early response
followed by a plateau in the persistent and recurrent
groups, and an initial plateau followed by a delayed
response in the persistent cases with tracks (Fig. 2 and
Table 2). In Figures 2 through 4 and 6, the proportion
of responders/nonresponders regarding foveal SRF,
CMT and SFCT are graphically reported. The three
anatomical parameters showed a bimodal response
with the proportion of responders systematically
exceeding the proportion of nonresponders.
In a subgroup analysis according to age, patients
younger than 51 years (the median age of the study
population), showed at 1, 3, and 6 months a
significant decrease in foveal SRF (P ¼ 0.0004, P ¼
0.0007, and P ¼ 0.0031, respectively) and CMT (P ¼
0.0017, P ¼ 0.0016, and P ¼ 0.0037, respectively),
Figure 2. Profile of foveal subretinal fluid in 54 eyes with nonresolving CSCR treated by mineralocorticoid-receptor antagonists (A), and
in three clinical CSCR subgroups: persistent (B), recurrent (C), and persistent with tracks (D). The areas of circular marks are proportional to
the number of responders (red) and nonresponders (blue). *P , 0.05 compared with baseline values (Wilcoxon paired test), color-filled
band: superior and inferior 95% confidence intervals.
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while patients older than 51 years presented a
significant decrease in both parameters at 3 and 6
months only (SRF, P¼ 0.016 and P¼ 0.021; CMT, P
¼ 0.011 and 0.039, respectively). Figure 6 illustrates
the delayed and less pronounced response in older
patients compared with younger ones.
Treatment Safety and Tolerance
Treatment-related side effects were observed in six
patients. Among 20 patients who received spirono-
lactone, one developed gynaecomastia, one had a
systolic blood pressure less than 100 mm Hg detected
by his attending physician without symptoms, and
two developed hyperkalemia (5.0 and 5.2 mEq/L).
Among 30 patients who received eplerenone, hyper-
kalemia was detected in two patients (5.0 and 5.7
mEq/L). All complications resolved after treatment
interruption (1 patient), continuation under surveil-
lance (2 patients), or switch from spironolactone to
eplerenone (3 patients). A case-by-case description of
these events is provided in Table 3.
Treatment Switch and Interruption
Among patients who received both treatments
sequentially, seven subjects switched from spirono-
lactone to eplerenone and one switched from epler-
enone to spironolactone. Beside side effects described
above, causes for treatment modifications are detailed
in Table 4. No subject discontinued the treatment
before 3 months. It was stopped in 11 patients after 3
to 6 months: in eight patients, resolution of foveal
SRF was observed, and three individuals refused to
continue the treatment.
At 6 months, there was no significant difference in
foveal SRF variation from baseline between patients
treated by spironolactone, eplerenone, or both drugs
sequentially:59,62, and73 lm, respectively (P .
0.5, Mann-Whitney U tests).
Discussion
In nonresolving CSCR patients treated with oral
MR-antagonists, a significant anatomical improve-
Figure 3. Profile of central macular thickness in 54 eyes with nonresolving CSCR treated by mineralocorticoid-receptor antagonists (A),
and in three clinical CSCR subgroups: persistent (B), recurrent (C), and persistent with tracks (D). The areas of circular marks are
proportional to the number of responders (red) and nonresponders (blue). *P , 0.05 compared with baseline values (Wilcoxon paired
test), color-filled band: superior and inferior 95% confidence intervals.
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ment was observed after 1, 3, and 6 months and visual
improvement was observed at 6 months. Treatment
produced only a limited number of side effects. These
results suggest that oral MR-antagonists have a
pharmacologic effect on CSCR eyes, as supported
by previous animal10 and clinical studies.12–15
When categorizing nonresolving CSCR cases into
persistent, recurrent and persistent-with-tracks, a
response to treatment was observed in all three
subgroups. Interestingly, the kinetics of anatomical
resolution indicated an earlier response to treatment
in persistent and recurrent cases as compared with the
persistent cases with tracks. This delayed response
suggests that MR-antagonists should be prescribed
for longer periods in persistent cases with tracks,
characterized by gravitational tracks on fundus
autofluorescence and more extended RPE disease on
fluorescein angiography, in order to obtain significant
anatomical benefits. Interestingly, in these eyes CMT
is a relevant clinical endpoint due to the high
frequency of intraretinal cysts and low amount of
SRF, and was significantly improved after treatment.
Moreover, persistent cases with tracks often present
an irreversible loss of photoreceptor outer segments,
as observed in the present study (Figure 5O and
Supplementary Table S1). Complete subretinal fluid
resolution may not be reached due to this morpho-
logical gap, which is otherwise bridged by elongated
outer segments. Patients aged 51 years or more also
showed a delayed response as compared with those
below 51 years, a finding consistent with the older age
of persistent cases with tracks, as observed here and
reported in the literature.16 Whether specific biolog-
ical mechanisms involved in advanced RPE disease
explain the delayed response of older, more chronic
cases to oral MR-antagonists remains to be elucidat-
ed.
Regarding the functional effects of treatment, a
significant improvement in BCVA was observed in
the overall cohort and the persistent CSCR group at 6
Figure 4. Profile of subfoveal choroidal thickness in 48 eyes with nonresolving CSCR treated by mineralocorticoid-receptor antagonists
(A), and in three clinical CSCR subgroups: persistent (B), recurrent (C), and persistent with tracks (D). The areas of circular marks are
proportional to the number of responders (red) and nonresponders (blue). *P , 0.05 compared with baseline values (Wilcoxon paired
test), color-filled band: superior and inferior 95% confidence intervals.
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months. In the recurrent group, the absence of
significant improvement may be related to the high
baseline BCVA levels. Patients presenting persistent
CSCR with tracks showed a moderate improvement
that failed to achieve significance due to the limited
number of subjects. Consistently with RPE damages
due to their long-standing disease, they also displayed
lower baseline and final BCVA levels than the other
CSCR subtypes. In these patients, initiation of
treatment at earlier time, and prolonged treatment
could avoid irreversible damage and should be further
evaluated.
Nonresolving CSCR patients often have bilateral
disease, as illustrated by the 40% of bilateral CSCR
observed in the present study. They often present
multiple leakage sites and areas of choroidal hyper-
permeability.20 This widespread involvement of the
choroid and RPE in CSCR pathogenesis is also
reflected by the diffuse choroidal thickening reported
in acute and chronic CSCR.21,22 Hence, compared
with focal treatments such as laser photocoagulation
and PDT, oral therapies have a systemic biodistribu-
tion and diffuse in target organs at cellular level. In
addition, rationale for treatment by eplerenone and
spironolactone rely on evidences that the MR is
expressed in the choroid and neuroretina, and is
implicated in CSCR pathogenesis.10,12,23
Both drugs have already been evaluated for the
treatment of nonresolving CSCR. In a prospective
pilot study, Bousquet et al.12 evaluated oral epler-
enone (25–50 mg/day) in 13 CSCR eyes without
improvement after 4 months, and observed a signif-
icant effect on foveal SRF and BCVA at 3 months. In
a retrospective series of 17 CSCR eyes presenting the
same characteristics and treated by oral eplerenone
(25–50 mg/day), Singh et al.13 reported similar results
up to 6 months after treatment initiation.14 In a
prospective series of 20 eyes with nonresolving CSCR
lasting longer than 6 weeks, Herold et al.13 evaluated
oral spironolactone (50 mg/day) and described an
improvement in SRF, CMT, and BCVA after 3
months. Finally, in a prospective, randomized,
double-blinded study Bousquet et al.15 evaluated
spironolactone (50 mg/day) versus placebo for 30
days followed by a crossover period of 30 days, on 16
eyes with SRF persisting for 3 months or more. They
Table 2. Treatment Effect According to the Three Clinical CSCR Subtypes
Total
(n ¼ 54 Eyes)
Persistent CSCR
(n ¼ 20 Eyes)
Recurrent CSCR
(n ¼ 19 Eyes)
Persistent CSCR
With Tracks
(n ¼ 15 Eyes)
Foveal subretinal fluid, lm (P value compared with baselinea)
Baseline 96 6 28 107 6 40 115 6 57 46 6 31
1 mo 68 6 25 (0.009) 83 6 47 (0.016) 66 6 40 (0.0002) 42 6 41 (0.94)
3 mo 40 6 17 (,0.0001) 33 6 24 (0.002) 43 6 33 (0.0006) 40 6 36 (0.47)
6 mo 37 6 18 (,0.0001) 36 6 25 (0.006) 50 6 40 (0.012) 16 6 16 (0.058)
Central macular thickness, lm (P value compared with baselinea)
Baseline 336 6 28 378 6 43 314 6 50 330 6 58
1 mo 316 6 28 (0.002) 337 6 50 (0.015) 277 6 32 (0.014) 318 6 66 (0.64)
3 mo 290 6 27 (,0.0001) 299 6 38 (0.020) 261 6 29 (0.0009) 311 6 81 (0.09)
6 mo 276 6 27 (0.0003) 303 6 45 (0.017) 264 6 21 (0.026) 281 6 83 (0.044)
Subfoveal choroidal thickness, lm (P value compared with baselinea)
Baseline 474 6 34 428 6 73 544 6 69 434 6 82
1 mo 465 6 40 (0.039) 396 6 64 (0.81) 538 6 72 (0.050) 429 6 72 (0.50)
3 mo 434 6 43 (0.0007) 367 6 67 (0.009) 516 6 62 (0.023) 408 6 67 (0.41)
6 mo 446 6 40 (,0.0001) 402 6 76 (0.008) 509 6 64 (0.0024) 410 6 70 (0.041)
Best-corrected visual acuity, LogMAR (P value compared with baselinea)
Baseline 0.28 6 0.09 0.25 6 0.12 0.13 6 0.06 0.52 6 0.25
1 mo 0.23 6 0.07 (0.24) 0.20 6 0.13 (0.014) 0.13 6 0.09 (0.93) 0.41 6 0.21 (1)
3 mo 0.25 6 0.09 (0.093) 0.21 6 0.14 (0.074) 0.10 6 0.08 (0.44) 0.52 6 0.27 (0.91)
6 mo 0.23 6 0.09 (0.041) 0.17 6 0.12 (0.018) 0.14 6 0.08 (0.82) 0.42 6 0.27 (0.16)
Mean values 695% confidence intervals. LogMAR, logarithm of the minimum angle of resolution.
a Wilcoxon paired signed-rank test.
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observed a significant reduction in SRF in the
spironolactone-treated eyes compared with the same
eyes during the placebo period. The present study,
collecting subjects from two different eye centers,
confirms these observations in a larger cohort, and
discriminates the effects of treatment between three
clinical subcategories of nonresolving CSCR, which,
to the best of our knowledge has not been previously
contemplated. Moreover, we have pooled data from
patients on spironolactone, eplerenone, or both drugs
sequentially, and observed no difference in efficacy
between both molecules, despite the higher binding
affinity of spironolactone for the MR compared with
eplerenone.24
In all three subgroups, a significant diminution in
SFCT was observed after 6 months. In persistent
CSCR, there was an overall SFCT diminution
compared with baseline, but a partial reincrease at 6
months, possibly caused by an on/off effect because 5
of 20 patients discontinued treatment after 3 months.
A decrease in SFCT has been previously observed in
CSCR after spontaneous resolution, half-dose PDT25
or treatment by oral MR-antagonists.15 These SFCT
variations further illustrate the role of choroidal
vasculature in CSCR pathogenesis. Unexpectedly,
we observed that eyes categorized as recurrent CSCR
had thicker choroids than those categorized as
persistent or persistent with tracks. Consistently, a
recent study evaluating CSCR recurrences after anti-
VEGF or PDT reported a lower reduction in SFCT
Figure 5. Optical coherence tomography showing the response to treatment by oral mineralocorticoid-receptor antagonists in three
eyes with nonresolving CSCR. (A–E) Eye with persistent CSCR for 4 months without improvement, showing a progressive decrease in
subretinal fluid after introduction of oral spironolactone, with complete resolution at 3 months, absence of recurrence and reconstitution
of the ellipsoid zone by 6 months. (F–J) Eye with recurrent CSCR without improvement after 4 months of observation, progressive
resolution 1 and 3 months following the introduction of oral eplerenone, with stability at 6 months. (K–O) Eye with persistent CSCR with
tracks and evidence of nonresolving subretinal fluid during 4 months. After initiation of oral eplerenone, subretinal fluid was still present
at 1 and 3 months, but a delayed, complete resolution was observed at 6 months.
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Figure 6. Profile of foveal subretinal fluid (A, B) and central macular thickness (C, D) in 54 eyes with nonresolving CSCR treated by
mineralocorticoid-receptor antagonists, according to age at treatment introduction: less than or equal to 51 years (A, C) and greater than
51 years (B, D). The areas of circular marks are proportional to the number of responders (red) and nonresponders (blue). *P , 0.05
compared with baseline values (Wilcoxon paired test), color-filled band: superior and inferior 95% confidence intervals.
Table 3. Description and Management of Side Effects Observed During Mineralocorticoid-Receptor Antagonist
Therapy
Case Treatment Side Effect Management of Side Effect
Sex, Age CSCR Type
Drug
(Dose, mg/d) Duration Category Effect Decision Resolution
M, 58 y Recurrent Spiro (50) 6 mo Endocrine Gynaecomastia Switch to Eple Yes
M, 46 y Recurrent Spiro (50) 3 mo Vascular Systolic blood
pressure
, 100 mm Hg
Switch to Eple Yes
M, 60 y Recurrent Spiro (50) 1 mo Electrolytic Kþ ¼ 5.0 mEq/L Continuation
of Spiro
Yes
M, 68 y Persistent Spiro (75) 3 mo Electrolytic Kþ ¼ 5.2 mEq/L Switch to Eple Yes
M, 67 y Persistent
with tracks
Eple (50) 3 mo Electrolytic Kþ ¼ 5.7 mEq/L Interruption Yes
M, 43 y Recurrent Eple (50) 3 mo Electrolytic Kþ ¼ 5.0 mEq/L Continuation
of Eple
Yes
Spiro, spironolactone; Eple, eplerenone.
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after resolution in recurrent eyes than in nonrecurrent
eyes,26 suggesting a link between thick choroids and
recurrence risk.
Limitations of this study include its retrospective
nature, the absence of a control group, the use of two
drugs from the same class, and the numerical
dispersion of clinical parameters between and within
the three CSCR subtypes, related to the clinical
heterogeneity of the disease.
To summarize, treatment by eplerenone or spiro-
nolactone for the management of long-standing
CSCR seemed to be beneficial and well-tolerated
when carefully monitored in real-life conditions, with
half of the patients with nonresolving foveal subret-
inal fluid showing a complete resolution 6 months
after treatment initiation. This study also demon-
strated the relevance of a clinical classification of
CSCR cases for future therapeutic trials and the
different treatment responses according to these
clinical phenotypes. Further prospective, controlled
studies are needed to evaluate appropriate doses and
durations of oral MR-antagonists in nonresolving
CSCR.
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